List of publications using NVP-BEZ 235 (Axon 1281) purchased from Axon Medchem 

(total 27 publication citations listed from 2009 to JUNE 2016)

Kim, Min-Jung, et al. "Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation." Journal of Korean medical science 31.3 (2016): 360-370. 

de Oliveira, Antonio CP, et al. "Poly (I: C) increases the expression of mPGES-1 and COX-2 in rat primary microglia." Journal of neuroinflammation 13.1 (2016): 11. 
Jalota-Badhwar, Archana, et al. "P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity." Molecular cancer therapeutics 14.5 (2015): 1095-1106.
*BEZ235 and AZD8055 are from Axon Medchem. 
Costales, Abran Q., et al. "Compounds and compositions as protein kinase inhibitors." U.S. Patent No. 8,859,548. 14 Oct. 2014.
*PD0325901, PD184352, SL327, LY294002, PI103, PIK75, PIK90, GDC0941, BEX235, AS252424, TGX221 are from Axon Medchem 
Schuler, Walter, Frank P. Stegmeier, and Markus Warmuth. "Use of a PKC inhibitor." U.S. Patent No. 8,748,428. 10 Jun. 2014.
* LY294002, PI103, PIK75, PIK90, AS252424, TGX221, GDC0941 are from Axon Medchem.

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
CC Thoreen, SA Kang, JW Chang, Q Liu, J Zhang, Y Gao, LJ Reichling, T Sim, DM Sabatini, NS Gray.
J. Biol. Chem. 2009, 284, 8023-8032.   DOI: 10.1074/jbc.M900301200

[Citation: 338, till August 9, 2012] 

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.
N Turner, MB Lambros, HM Horlings, A Pearson, R Sharpe, R Natrajan, F C Geyer, M van Kouwenhove, B Kreike, A Mackay, A Ashworth, MJ van de Vijver, JS Reis-Filho.
Oncogene, 2010, 29, 2013–202. doi:10.1038/onc.2009.489
[Citation: 63, till August 9, 2012]

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia.
F Chiarini, C Grimaldi, F Ricci, PL Tazzari, C Evangelisti, A Ognibene, M Battistelli, E Falcieri, F Melchionda, A Pession, P Pagliaro, JA McCubrey, AM Martelli.
Cancer Res. 2010, 7, 8097.   doi: 10.1158/0008-5472.CAN-10-1814
[Citation: 37, till August 9, 2012]

Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells.
J Sunayama,, KI Matsuda, A Sato, K Tachibana, K Suzuki, Y Narita, S Shibui, K Sakurada, T Kayama, A Tomiyama, C Kitanaka. 
STEM CELLS, 2010, 28, 1930–1939.   DOI: 10.1002/stem.521

Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
J Sunayama, A Sato, KI Matsuda, K Tachibana, K Suzuki, Y Narita, S Shibui, K Sakurada, T Kayama, A Tomiyama, C Kitanaka.
Neuro. Oncol. 2010,12 (12), 1205-1219.   DOI: 10.1093/neuonc/noq103

The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors
D Castelletti, G Fiaschetti, V Di Dato, U Ziegler, C Kumps, K De Preter, M Zollo, F Speleman, T Shalaby, D De Martino, T Berg, A Eggert, A Arcaro, MA Grotzer.
Mol. Cancer Ther. 2010, 9, 3145.   DOI: 10.1158/1535-7163.MCT-10-0539

BacMam-Enabled LanthaScreen® Cellular Assays for PI3K/Akt Pathway Compound Profiling in Disease-Relevant Cell Backgrounds.
CB Carlson, MJ Mashock and K Bi
J. Biomol. Screen. 2010, 15 (3) 327-334.   doi: 10.1177/1087057109357788

Aberrant AKT activation drives well-differentiated liposarcoma.
A Gutierrez, EL Snyderc, A Marino-Enriquez, YX Zhang, S Sioletic, E Kozakewich, R Grebliunaite, WB Ou, E Sicinska, CP Raut, GD Demetri, AR Perez-Atayde, AJ Wagner, JA Fletcher, CDM Fletcher, AT Look.
PNAS, 2011, 108 (39), 16386-16391.    DOI: 10.1073/pnas.1106127108

Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia.
ACP de Oliveira, E Candelario-Jalil, J Langbein, L Wendeburg, HS Bhatia, JCM Schlachetzki, K Biber, BL Fiebich.
J. Neuroinflam. 2012, 9, 2.   DOI:10.1186/1742-2094-9-2

Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor p57Kip2.
DT Worster, T Schmelzle, NL Solimini, ES Lightcap, B Millard, GB Mills, JS Brugge, JG Albeck, 
Sci. Signal. 2012, 5(214), ra19.  DOI: 10.1126/scisignal.200198

Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype.
C Stengel, CW Cheung, J Quinn, K Yong, A Khwaja. - -
Leukemia, 2012, 1–10.  DOI: 10.1038/leu.2012.69

Novel zebrafish model reveals a critical role for MAPK in lymphangiogenesis
RD Fevurly, S Hasso, A Fye, SJ Fishman, J Chan.
J. Pediatric Surgery, 2012, 47 (1), 177–182. [online]

Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia.
AC de Oliveira, E Candelario-Jalil, J Langbein, L Wendeburg, HS Bhatia, JCM Schlachetzki, K Biber and BL Fiebich.
J. Neuroinflammatory. 2012, 9, 2.  [online]

Compounds and compositions as protein kinase inhibitors.
AQ Costales, S Huang, JX Jin, Z Liu, S Pecchi, D Poon, J Tellew, and Q Zhang.
U.S. Patent 8,242,260, issued August 14, 2012.

AM Madera, D Poon, and A Smith. 
U.S. Patent No. 20,130,096,149. 18 Apr. 2013.

Next‐generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN‐amplified neuroblastoma.
A Schramm, J Köster, T Marschall, M Martin, M Schwermer, K Fielitz, G Büchel, M Barann, D Esser, P Rosenstiel, S Rahmann, A Eggert, JH Schulte.
Int. J. Cancer 2013, 132 (3), E106-E115.
Read more:

PDK1 Signaling Towards PLK1-Myc Activation Confers Oncogenic Transformation and Tumor Initiating Cell Activation and Resistance to mTOR-targeted Therapy.
J Tan, Z Li, PL Lee, P Guan, MY Aau, ST Lee, M Feng, CZ Lim, EYJ Lee, ZN Wee, YC Lim, RKM Karuturi and Q Yu.
Cancer Discovery, Published Online July 25, 2013.
Read more:
... 60 inhibitors including BEZ235 were purchased from Axon Medchem 

Compounds and Compositions as Protein Kinase Inhibitors
US 20140011825 A1
Read more:

Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion Of MIR17HG In Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity. 
Pais, F., Lee, S., Rodic, V., Barth, M. J., Cairo, M. S., & Hermiston, M. L. (2013). 
Blood, 122(21), 243-243.
Read more:

Chondrosarcoma models: understanding chemoresistance mechanisms for use in targeted treatment 
Oosterwijk, J. G. V. (2013). 
(Doctoral dissertation, Department of Pathology, Faculty of Medicine, Leiden University Medical Center (LUMC).
Read more:

RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity.
J Kawasaki, S Aegerter, RD Fevurly, A Mammoto, T Mammoto, M Sahin, JD Mably, SJ Fishman and J Chan.
J Clin Invest. 2014, doi:10.1172/JCI67084. 
* GDC0941 and BEZ235 from Axon Medchem

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
S Zhou, L Liu, H Li, G Eilers, Y Kuang, S Shi, Z Yan, X Li, JM Corson, F Meng, H. Zhou, Q Sheng, JA Fletcher, WB Qu.
Br. J. Cancer (2014) 110, 2479–2488. doi:10.1038/bjc.2014.220
Read more:

(This is an incomplete list, updated in JUNE-2016)

Please wait...